Table I.
No. | Age | Gender | Histopathological diagnosis | EML4-ALK transcript |
---|---|---|---|---|
1 | 48 | Female | Adenocarcinoma | Variant 1 |
2 | 49 | Male | Adenocarcinoma | Variant 1 |
3 | 66 | Male | Adenocarcinoma | Variant 1 |
4 | 46 | Female | Adenocarcinoma | Variant 2 |
5 | 57 | Male | Adenocarcinoma | Variant 2 |
6 | 79 | Male | Adenocarcinoma | Variant 2 |
7 | 33 | Female | Adenosquamous carcinoma | Variants 3a and 3b |
8 | 63 | Female | Adenocarcinoma | Variants 3a and 3b |
9 | 83 | Male | Adenocarcinoma | Variants 3a and 3b |
10 | 58 | Male | Adenocarcinoma | A novel varianta |
11 | 36 | Female | Adenocarcinoma | Not examinedb |
12 | 69 | Female | Squamous cell carcinoma | Not examinedb |
Exon 14 of EML4 is connected to a 2-bp fragment that in turn is ligated to the nucleotide at position 53 of exon 20 of ALK.
Due to the absence of an RNA sample, RT-PCR analysis for ALK fusions was not performed.